 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.
SUMMARIES FOR PATIENTS
Therapy to Prevent Stroke in Patients with Atrial Fibrillation
5 October 1999 | Volume 131 Issue 7 | Page 492
Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians-American Society of Internal Medicine.
The summary below is from the full report titled "Antithrombotic Therapy To Prevent Stroke in Patients with Atrial Fibrillation: A Meta-Analysis." It is in the 5 October 1999 issue of Annals of Internal Medicine (volume 131, pages 492-501). The authors are R.G. Hart, O. Benavente, R. McBride, and L.A. Pearce.
What is the problem and what is known about it so far?
Atrial fibrillation is a kind of irregular heart rhythm. People with atrial fibrillation sometimes develop blood clots in their hearts. These clots can lead to stroke if the blood clots travel from the heart to the brain. Strokes are the neurologic problems, such as weakness or difficulty with speech, that result when brain tissue does not get enough blood. Antithrombotic medicines like warfarin or aspirin make the blood take longer to clot. These medicines can therefore prevent stroke in many people with atrial fibrillation. But doctors are sometimes reluctant to prescribe and patients can be reluctant to take these medications because they can lead to bleeding complications like bleeding ulcers or bleeding into the brain.
Why did the researchers do this particular study?
In recent years, different researchers have conducted 16 separate studies of antithrombotic medications for atrial fibrillation. The present researchers combined the data from these previous studies to better estimate the ability of these medications to prevent stroke and their likelihood of causing bleeding complications for patients with atrial fibrillation.
Who was studied?
In the 16 studies that were analyzed, there were a total of 9874 patients.
How was the study done?
Using computers, the researchers searched the medical literature to identify all studies of antithrombotic medications to prevent stroke for patients with atrial fibrillation. They included only randomized, controlled trials where patients received warfarin, aspirin, or no treatment. In a randomized, controlled trial, each patient has an equal chance of receiving one of the treatments. Studies are designed like this when it really is not clear that one treatment is better than another or better than no treatment at all. Using a statistical method called meta-analysis, the researchers combined the findings of the 16 separate studies.
What did the researchers find?
Warfarin and aspirin reduced the chances of stroke for patients with atrial fibrillation. Warfarin prevented more strokes than aspirin. Major bleeding complications did not outweigh these benefits.
What were the limitations of the study?
Combining the results of separate studies can be misleading, especially if the studies are very different from each other.
What are the implications of the study?
Physicians should prescribe antithrombotic medications to most patients with atrial fibrillation, except when particular patients have conditions that put them at high risk for bleeding complications. The choice between warfarin and aspirin depends on the inherent risk for stroke: Patients with atrial fibrillation who have the highest stroke risk benefit most from warfarin.
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  Y. Grad, H. Sievert, B. Nishri, G. W. Stone, B. T. Katzen, O. Yodfat, R. Higashida, D. Harris, A. K. Wakhloo, Y. Assaf, et al. A Novel Endovascular Device for Emboli Rerouting: Part I: Evaluation in a Swine Model Stroke, October 1, 2008; 39(10): 2860 - 2866. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Choudhury, I. Chung, N. Panja, J. Patel, and G. Y. H. Lip Soluble CD40 Ligand, Platelet Surface CD40 Ligand, and Total Platelet CD40 Ligand in Atrial Fibrillation: Relationship to Soluble P-Selectin, Stroke Risk Factors, and Risk Factor Intervention Chest, September 1, 2008; 134(3): 574 - 581. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A M Veitch, T P Baglin, A H Gershlick, S M Harnden, R Tighe, and S Cairns Guidelines for the management of anticoagulant and antiplatelet therapy in patients undergoing endoscopic procedures Gut, September 1, 2008; 57(9): 1322 - 1329. [Full Text] [PDF]
|
|
|
|
 |
|
 I van Wijk, P J Koudstaal, L J Kappelle, J van Gijn, J W Gorter, A Algra, and for the LiLAC Study Group Long-term occurrence of death and cardiovascular events in patients with transient ischaemic attack or minor ischaemic stroke: comparison between arterial and cardiac source of the index event J. Neurol. Neurosurg. Psychiatry, August 1, 2008; 79(8): 895 - 899. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Meiltz, M. Zimmermann, P. Urban, A. Bloch, and on behalf of the Association of Cardiologists of t Atrial fibrillation management by practice cardiologists: a prospective survey on the adherence to guidelines in the real world Europace, June 1, 2008; 10(6): 674 - 680. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Ansell, J. Hirsh, E. Hylek, A. Jacobson, M. Crowther, and G. Palareti Pharmacology and Management of the Vitamin K Antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 160S - 198S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Schulman, R. J. Beyth, C. Kearon, and M. N. Levine Hemorrhagic Complications of Anticoagulant and Thrombolytic Treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 257S - 298S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Douketis, P. B. Berger, A. S. Dunn, A. K. Jaffer, A. C. Spyropoulos, R. C. Becker, and J. Ansell The Perioperative Management of Antithrombotic Therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 299S - 339S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. E. Singer, G. W. Albers, J. E. Dalen, M. C. Fang, A. S. Go, J. L. Halperin, G. Y. H. Lip, and W. J. Manning Antithrombotic Therapy in Atrial Fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 546S - 592S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Healey, R. G. Hart, J. Pogue, M. A. Pfeffer, S. H. Hohnloser, R. De Caterina, G. Flaker, S. Yusuf, and S. J. Connolly Risks and Benefits of Oral Anticoagulation Compared With Clopidogrel Plus Aspirin in Patients With Atrial Fibrillation According to Stroke Risk: The Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE-W) Stroke, May 1, 2008; 39(5): 1482 - 1486. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G Y H Lip and C J Boos Antithrombotic treatment in atrial fibrillation Postgrad. Med. J., May 1, 2008; 84(991): 252 - 258. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. L. Hansen, N. Gadsboll, G. H. Gislason, S. Z. Abildstrom, T. K. Schramm, F. Folke, J. Friberg, R. Sorensen, S. Rasmussen, H. E. Poulsen, et al. Atrial fibrillation pharmacotherapy after hospital discharge between 1995 and 2004: a shift towards beta-blockers Europace, April 1, 2008; 10(4): 395 - 402. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K Gjesdal, J Feyzi, and S B Olsson Digitalis: a dangerous drug in atrial fibrillation? An analysis of the SPORTIF III and V data Heart, February 1, 2008; 94(2): 191 - 196. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. G.G. Turpie New oral anticoagulants in atrial fibrillation Eur. Heart J., January 2, 2008; 29(2): 155 - 165. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Gattellari, J. Worthington, N. Zwar, and S. Middleton Barriers to the Use of Anticoagulation for Nonvalvular Atrial Fibrillation: A Representative Survey of Australian Family Physicians Stroke, January 1, 2008; 39(1): 227 - 230. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. A. Nutescu ASHP Therapeutic Position Statement on Antithrombotic Therapy in Chronic Atrial Fibrillation Am. J. Health Syst. Pharm., November 1, 2007; 64(21): 2281 - 2291. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Hughes, G.Y.H. Lip, and on behalf of the Guideline Development Group for t Risk factors for anticoagulation-related bleeding complications in patients with atrial fibrillation: a systematic review QJM, October 1, 2007; 100(10): 599 - 607. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Habara, K. Dote, M. Kato, S. Sasaki, K. Goto, H. Takemoto, D. Hasegawa, and O. Matsuda Prediction of left atrial appendage thrombi in non-valvular atrial fibrillation Eur. Heart J., September 2, 2007; 28(18): 2217 - 2222. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Yamashita, A. Sekiguchi, T. Kato, T. Tsuneda, Y.-k. Iwasaki, K. Sagara, H. Iinuma, H. Sawada, and T. Aizawa Angiotensin type 1 receptor blockade prevents endocardial dysfunction of rapidly paced atria in rats Journal of Renin-Angiotensin-Aldosterone System, September 1, 2007; 8(3): 127 - 132. [Abstract] [PDF]
|
|
|
|
|
|
S. T. Engelter, T. Brandt, S. Debette, V. Caso, C. Lichy, A. Pezzini, S. Abboud, A. Bersano, R. Dittrich, C. Grond-Ginsbach, et al. Antiplatelets Versus Anticoagulation in Cervical Artery Dissection Stroke, September 1, 2007; 38(9): 2605 - 2611. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Baruch, B. F. Gage, J. Horrow, S. Juul-Moller, A. Labovitz, M. Persson, and M. Zabalgoitia Can Patients at Elevated Risk of Stroke Treated With Anticoagulants Be Further Risk Stratified? Stroke, September 1, 2007; 38(9): 2459 - 2463. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Thomson, M. Eccles, R. Wood, and D. J. Chinn A Cautionary Note on Data Sources for Evidence-Based Clinical Decisions: Warfarin and Stroke Prevention Med Decis Making, August 1, 2007; 27(4): 438 - 447. [Abstract] [PDF]
|
|
|
|
 |
|
 S. J. Connolly, J. Eikelboom, M. O'Donnell, J. Pogue, and S. Yusuf Challenges of Establishing New Antithrombotic Therapies in Atrial Fibrillation Circulation, July 24, 2007; 116(4): 449 - 455. [Full Text] [PDF]
|
|
|
|
 |
|
 R. G. Hart, L. A. Pearce, and M. I. Aguilar Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation Ann Intern Med, June 19, 2007; 146(12): 857 - 867. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. G Thomson, M. P Eccles, I N. Steen, J. Greenaway, L. Stobbart, M. J Murtagh, and C. R May A patient decision aid to support shared decision-making on anti-thrombotic treatment of patients with atrial fibrillation: randomised controlled trial Qual. Saf. Health Care, June 1, 2007; 16(3): 216 - 223. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Authors/Task Force Members, L. Ryden, E. Standl, M. Bartnik, G. V. d. Berghe, J. Betteridge, M.-J. de Boer, F. Cosentino, B. Jonsson, M. Laakso, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: full text: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) Eur. Heart J. Suppl., June 1, 2007; 9(suppl_C): C3 - C74. [Full Text] [PDF]
|
|
|
|
|
|
E. M. Hylek, C. Evans-Molina, C. Shea, L. E. Henault, and S. Regan Major Hemorrhage and Tolerability of Warfarin in the First Year of Therapy Among Elderly Patients With Atrial Fibrillation Circulation, May 29, 2007; 115(21): 2689 - 2696. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Holbrook, R. Labiris, C. H. Goldsmith, K. Ota, S. Harb, and R. J. Sebaldt Influence of decision aids on patient preferences for anticoagulant therapy: a randomized trial Can. Med. Assoc. J., May 22, 2007; 176(11): 1583 - 1587. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Y.H. Lip and T. Watson Stroke prevention in atrial fibrillation: antiplatelet therapy revisited Eur. Heart J., April 12, 2007; (2007) ehm077v1. [Full Text] [PDF]
|
|
|
|
|
|
R. De Caterina, S. Husted, L. Wallentin, G. Agnelli, F. Bachmann, C. Baigent, J. Jespersen, S. D. Kristensen, G. Montalescot, A. Siegbahn, et al. Anticoagulants in heart disease: current status and perspectives Eur. Heart J., April 10, 2007; (2007) ehl492v1. [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Morrison, N. Gainsborough, and C. Rajkumar Warfarin versus aspirin in the elderly in primary prophylaxis for atrial fibrillation Age Ageing, March 1, 2007; 36(2): 117 - 119. [Full Text] [PDF]
|
|
|
|
|
|
P. T. Akins, H. A. Feldman, R. G. Zoble, D. Newman, S. G. Spitzer, H.-C. Diener, and G. W. Albers Secondary Stroke Prevention With Ximelagatran Versus Warfarin in Patients With Atrial Fibrillation: Pooled Analysis of SPORTIF III and V Clinical Trials Stroke, March 1, 2007; 38(3): 874 - 880. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Onalan and E. Crystal Left Atrial Appendage Exclusion for Stroke Prevention in Patients With Nonrheumatic Atrial Fibrillation Stroke, February 1, 2007; 38(2): 624 - 630. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Authors/Task Force Members, L. Ryden, E. Standl, M. Bartnik, G. Van den Berghe, J. Betteridge, M.-J. de Boer, F. Cosentino, B. Jonsson, M. Laakso, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) Eur. Heart J., January 1, 2007; 28(1): 88 - 136. [Full Text] [PDF]
|
|
|
|
|
|
A. K. Das, P. D. Willcoxson, O. J. Corrado, and R. M. West The impact of long-term warfarin on the quality of life of elderly people with atrial fibrillation Age Ageing, January 1, 2007; 36(1): 95 - 97. [Full Text] [PDF]
|
|
|
|
|
|
R. Nieuwlaat, A. Capucci, G. Y.H. Lip, S. B. Olsson, M. H. Prins, F. H. Nieman, J. Lopez-Sendon, P. E. Vardas, E. Aliot, M. Santini, et al. Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation Eur. Heart J., December 2, 2006; 27(24): 3018 - 3026. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Dunning, T. Treasure, M. Versteegh, S. A.M. Nashef, and on behalf of the EACTS Audit and Guidelines Commit Guidelines on the prevention and management of de novo atrial fibrillation after cardiac and thoracic surgery Eur. J. Cardiothorac. Surg., December 1, 2006; 30(6): 852 - 872. [Full Text] [PDF]
|
|
|
|
|
|
E. M. Hylek, L. E. Henault, C. Evans-Molina, C. Shea, and S. Regan Response to Letter by Testa et al Stroke, December 1, 2006; 37(12): 2868 - 2868. [Full Text] [PDF]
|
|
|
|
 |
|
 G. W. Albers, H.-C. Diener, L. Frison, M. Grind, J. Horrow, M. Nevinson, S. B. Olsson, S. Partridge, P. Petersen, A. Vahanian, et al. Trials and Tribulations of Noninferiority: The Ximelagatran Experience J. Am. Coll. Cardiol., September 5, 2006; 48(5): 1058 - 1058. [Full Text] [PDF]
|
|
|
|
|
|
Writing Committee Members, V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society Europace, September 1, 2006; 8(9): 651 - 745. [Full Text] [PDF]
|
|
|
|
|
|
V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, J. E. Lowe, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation--Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society J. Am. Coll. Cardiol., August 15, 2006; 48(4): 854 - 906. [Full Text] [PDF]
|
|
|
|
|
|
V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, J. E. Lowe, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society J. Am. Coll. Cardiol., August 15, 2006; 48(4): e149 - e246. [Full Text] [PDF]
|
|
|
|
|
|
V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, J. E. Lowe, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society Circulation, August 15, 2006; 114(7): e257 - e354. [Full Text] [PDF]
|
|
|
|
|
|
V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, J. E. Lowe, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation--Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society Circulation, August 15, 2006; 114(7): 700 - 752. [Full Text] [PDF]
|
|
|
|
|
|
Authors/Task Force Members, V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation executive summary: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society Eur. Heart J., August 2, 2006; 27(16): 1979 - 2030. [Full Text] [PDF]
|
|
|
|
|
|
M. Gomberg-Maitland, N. K. Wenger, J. Feyzi, M. Lengyel, A. S. Volgman, P. Petersen, L. Frison, and J. L. Halperin Anticoagulation in women with non-valvular atrial fibrillation in the stroke prevention using an oral thrombin inhibitor (SPORTIF) trials Eur. Heart J., August 2, 2006; 27(16): 1947 - 1953. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Friberg, N. Hammar, M. Ringh, H. Pettersson, and M. Rosenqvist Stroke prophylaxis in atrial fibrillation: who gets it and who does not?: Report from the Stockholm Cohort-study on Atrial Fibrillation (SCAF-study) Eur. Heart J., August 2, 2006; 27(16): 1954 - 1964. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. J. Hankey Potential New Risk Factors for Ischemic Stroke: What Is Their Potential? Stroke, August 1, 2006; 37(8): 2181 - 2188. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Harmsen, G. Lappas, A. Rosengren, and L. Wilhelmsen Long-Term Risk Factors for Stroke: Twenty-Eight Years of Follow-Up of 7457 Middle-Aged Men in Goteborg, Sweden Stroke, July 1, 2006; 37(7): 1663 - 1667. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. J. Cooper, A. J. Sutton, G. Lu, and K. Khunti Mixed comparison of stroke prevention treatments in individuals with nonrheumatic atrial fibrillation. Arch Intern Med, June 26, 2006; 166(12): 1269 - 1275. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. B. Goldstein, R. Adams, M. J. Alberts, L. J. Appel, L. M. Brass, C. D. Bushnell, A. Culebras, T. J. DeGraba, P. B. Gorelick, J. R. Guyton, et al. Primary Prevention of Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association Stroke Council: Cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: The American Academy of Neurology affirms the value of this guideline. Circulation, June 20, 2006; 113(24): e873 - e923. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. B. Goldstein, R. Adams, M. J. Alberts, L. J. Appel, L. M. Brass, C. D. Bushnell, A. Culebras, T. J. DeGraba, P. B. Gorelick, J. R. Guyton, et al. Primary Prevention of Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association Stroke Council: Cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: The American Academy of Neurology affirms the value of this guideline. Stroke, June 1, 2006; 37(6): 1583 - 1633. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 |
Article
